
According to Benzinga Pro data, during Q4, Cidara Therapeutics (NASDAQ:CDTX) posted sales of $7.22 million. Earnings were up 7.08%, but Cidara Therapeutics still reported an overall loss of $16.80 million. Cidara Therapeutics collected $7.08 million in revenue during Q3, but reported earnings showed a $18.08 million loss.